TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4 - PubMed (original) (raw)

TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4

A Nakao et al. EMBO J. 1997.

Abstract

Smad family members are newly identified essential intracellular signalling components of the transforming growth factor-beta (TGF-beta) superfamily. Smad2 and Smad3 are structurally highly similar and mediate TGF-beta signals. Smad4 is distantly related to Smads 2 and 3, and forms a heteromeric complex with Smad2 after TGF-beta or activin stimulation. Here we show that Smad2 and Smad3 interacted with the kinase-deficient TGF-beta type I receptor (TbetaR)-I after it was phosphorylated by TbetaR-II kinase. TGF-beta1 induced phosphorylation of Smad2 and Smad3 in Mv1Lu mink lung epithelial cells. Smad4 was found to be constitutively phosphorylated in Mv1Lu cells, the phosphorylation level remaining unchanged upon TGF-beta1 stimulation. Similar results were obtained using HSC4 cells, which are also growth-inhibited by TGF-beta. Smads 2 and 3 interacted with Smad4 after TbetaR activation in transfected COS cells. In addition, we observed TbetaR-activation-dependent interaction between Smad2 and Smad3. Smads 2, 3 and 4 accumulated in the nucleus upon TGF-beta1 treatment in Mv1Lu cells, and showed a synergistic effect in a transcriptional reporter assay using the TGF-beta-inducible plasminogen activator inhibitor-1 promoter. Dominant-negative Smad3 inhibited the transcriptional synergistic response by Smad2 and Smad4. These data suggest that TGF-beta induces heteromeric complexes of Smads 2, 3 and 4, and their concomitant translocation to the nucleus, which is required for efficient TGF-beta signal transduction.

PubMed Disclaimer

Similar articles

• Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
  Subramanian G, Schwarz RE, Higgins L, McEnroe G, Chakravarty S, Dugar S, Reiss M. Subramanian G, et al. Cancer Res. 2004 Aug 1;64(15):5200-11. doi: 10.1158/0008-5472.CAN-04-0018. Cancer Res. 2004. PMID: 15289325
• Lack of transforming growth factor-beta type II receptor expression in human retinoblastoma cells.
  Horie K, Yamashita H, Mogi A, Takenoshita S, Miyazono K. Horie K, et al. J Cell Physiol. 1998 Jun;175(3):305-13. doi: 10.1002/(SICI)1097-4652(199806)175:3<305::AID-JCP8>3.0.CO;2-S. J Cell Physiol. 1998. PMID: 9572475
• Interaction between Smad anchor for receptor activation and Smad3 is not essential for TGF-beta/Smad3-mediated signaling.
  Goto D, Nakajima H, Mori Y, Kurasawa K, Kitamura N, Iwamoto I. Goto D, et al. Biochem Biophys Res Commun. 2001 Mar;281(5):1100-5. doi: 10.1006/bbrc.2001.4489. Biochem Biophys Res Commun. 2001. PMID: 11243848
• Functional analysis of the TGFbeta receptor/Smad pathway through gene ablation in mice.
  Goumans MJ, Mummery C. Goumans MJ, et al. Int J Dev Biol. 2000 Apr;44(3):253-65. Int J Dev Biol. 2000. PMID: 10853822 Review.
• Transforming growth factor-β signalling: role and consequences of Smad linker region phosphorylation.
  Kamato D, Burch ML, Piva TJ, Rezaei HB, Rostam MA, Xu S, Zheng W, Little PJ, Osman N. Kamato D, et al. Cell Signal. 2013 Oct;25(10):2017-24. doi: 10.1016/j.cellsig.2013.06.001. Epub 2013 Jun 11. Cell Signal. 2013. PMID: 23770288 Review.

Cited by

• C1orf106 (INAVA) Is a SMAD3-Dependent TGF-β Target Gene That Promotes Clonogenicity and Correlates with Poor Prognosis in Breast Cancer.
  Strathearn LS, Spender LC, Schoenherr C, Mason S, Edwards R, Blyth K, Inman GJ. Strathearn LS, et al. Cells. 2024 Sep 12;13(18):1530. doi: 10.3390/cells13181530. Cells. 2024. PMID: 39329715 Free PMC article.
• Involvement of mitogen- and stress-activated protein kinase 1 in BMP-6-induced chondrocyte differentiation.
  Nakano N, Tashiro E, Shimada T, Ebisawa M, Kojima S, Ayabe K, Yamamoto Y, Maeda S, Itoh F, Itoh S. Nakano N, et al. J Biol Chem. 2024 Sep 21;300(11):107806. doi: 10.1016/j.jbc.2024.107806. Online ahead of print. J Biol Chem. 2024. PMID: 39307301 Free PMC article.
• Advancements in TGF-β Targeting Therapies for Head and Neck Squamous Cell Carcinoma.
  Britton WR, Cioffi I, Stonebraker C, Spence M, Okolo O, Martin C, Henick B, Nakagawa H, Parikh AS. Britton WR, et al. Cancers (Basel). 2024 Aug 31;16(17):3047. doi: 10.3390/cancers16173047. Cancers (Basel). 2024. PMID: 39272905 Free PMC article. Review.
• Geniposide ameliorates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-β/Smad and p38MAPK signaling pathways.
  Yin JB, Wang YX, Fan SS, Shang WB, Zhu YS, Peng XR, Zou C, Zhang X. Yin JB, et al. PLoS One. 2024 Sep 6;19(9):e0309833. doi: 10.1371/journal.pone.0309833. eCollection 2024. PLoS One. 2024. PMID: 39240867 Free PMC article.
• Inhibin subunit beta B (INHBB): an emerging role in tumor progression.
  Liu Y, Zhou Q, Zou G, Zhang W. Liu Y, et al. J Physiol Biochem. 2024 Aug 26. doi: 10.1007/s13105-024-01041-y. Online ahead of print. J Physiol Biochem. 2024. PMID: 39183219 Review.

References

1. 1. J Biol Chem. 1984 Sep 10;259(17):10995-1000 - PubMed
2. 1. Nature. 1996 Sep 12;383(6596):168-72 - PubMed
3. 1. Exp Cell Res. 1990 Apr;187(2):263-9 - PubMed
4. 1. Cell. 1993 Nov 19;75(4):681-92 - PubMed
5. 1. Science. 1994 Apr 1;264(5155):101-4 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • BioCyc
  • Gene Ontology
  • GlyGen glycoinformatics resource

• Miscellaneous

  • NCI CPTAC Assay Portal